vs
COMSCORE, INC.（SCOR）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
COMSCORE, INC.的季度营收约是Vericel Corp的1.0倍（$93.5M vs $92.9M），Vericel Corp净利率更高（25.0% vs 3.2%，领先21.8%），Vericel Corp同比增速更快（23.3% vs -1.5%），Vericel Corp自由现金流更多（$12.8M vs $2.9M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 3.8%）
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
SCOR vs VCEL — 直观对比
营收规模更大
SCOR
是对方的1.0倍
$92.9M
营收增速更快
VCEL
高出24.8%
-1.5%
净利率更高
VCEL
高出21.8%
3.2%
自由现金流更多
VCEL
多$9.9M
$2.9M
两年增速更快
VCEL
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $93.5M | $92.9M |
| 净利润 | $3.0M | $23.2M |
| 毛利率 | 41.0% | 78.7% |
| 营业利润率 | 7.0% | 24.1% |
| 净利率 | 3.2% | 25.0% |
| 营收同比 | -1.5% | 23.3% |
| 净利润同比 | -3.7% | 17.3% |
| 每股收益（稀释后） | $9.50 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收SCORVCEL
| Q4 25 | $93.5M | $92.9M | ||
| Q3 25 | $88.9M | $67.5M | ||
| Q2 25 | $89.4M | $63.2M | ||
| Q1 25 | $85.7M | $52.6M | ||
| Q4 24 | $94.9M | $75.4M | ||
| Q3 24 | $88.5M | $57.9M | ||
| Q2 24 | $85.8M | $52.7M | ||
| Q1 24 | $86.8M | $51.3M |
净利润SCORVCEL
| Q4 25 | $3.0M | $23.2M | ||
| Q3 25 | $453.0K | $5.1M | ||
| Q2 25 | $-9.5M | $-553.0K | ||
| Q1 25 | $-4.0M | $-11.2M | ||
| Q4 24 | $3.1M | $19.8M | ||
| Q3 24 | $-60.6M | $-901.0K | ||
| Q2 24 | $-1.7M | $-4.7M | ||
| Q1 24 | $-1.1M | $-3.9M |
毛利率SCORVCEL
| Q4 25 | 41.0% | 78.7% | ||
| Q3 25 | 40.6% | 73.5% | ||
| Q2 25 | 40.6% | 73.7% | ||
| Q1 25 | 39.6% | 69.0% | ||
| Q4 24 | 42.4% | 77.6% | ||
| Q3 24 | 41.2% | 71.9% | ||
| Q2 24 | 39.5% | 69.5% | ||
| Q1 24 | 42.3% | 68.9% |
营业利润率SCORVCEL
| Q4 25 | 7.0% | 24.1% | ||
| Q3 25 | 1.9% | 5.1% | ||
| Q2 25 | -1.9% | -3.2% | ||
| Q1 25 | -2.4% | -24.3% | ||
| Q4 24 | 4.1% | 24.5% | ||
| Q3 24 | -67.4% | -4.3% | ||
| Q2 24 | -2.2% | -11.5% | ||
| Q1 24 | -2.2% | -10.7% |
净利率SCORVCEL
| Q4 25 | 3.2% | 25.0% | ||
| Q3 25 | 0.5% | 7.5% | ||
| Q2 25 | -10.6% | -0.9% | ||
| Q1 25 | -4.7% | -21.4% | ||
| Q4 24 | 3.3% | 26.3% | ||
| Q3 24 | -68.5% | -1.6% | ||
| Q2 24 | -2.0% | -8.9% | ||
| Q1 24 | -1.2% | -7.5% |
每股收益（稀释后）SCORVCEL
| Q4 25 | $9.50 | $0.46 | ||
| Q3 25 | $-0.86 | $0.10 | ||
| Q2 25 | $-2.73 | $-0.01 | ||
| Q1 25 | $-1.66 | $-0.23 | ||
| Q4 24 | $-0.47 | $0.40 | ||
| Q3 24 | $-12.79 | $-0.02 | ||
| Q2 24 | $-1.19 | $-0.10 | ||
| Q1 24 | $-1.08 | $-0.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $23.6M | $137.5M |
| 总债务越低越好 | $41.5M | — |
| 股东权益账面价值 | $111.4M | $354.6M |
| 总资产 | $407.7M | $488.0M |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资SCORVCEL
| Q4 25 | $23.6M | $137.5M | ||
| Q3 25 | $26.7M | $135.4M | ||
| Q2 25 | $26.0M | $116.9M | ||
| Q1 25 | $31.0M | $112.9M | ||
| Q4 24 | $29.9M | $116.2M | ||
| Q3 24 | $20.0M | $101.7M | ||
| Q2 24 | $14.7M | $102.5M | ||
| Q1 24 | $18.7M | $110.6M |
总债务SCORVCEL
| Q4 25 | $41.5M | — | ||
| Q3 25 | $41.4M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $41.3M | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益SCORVCEL
| Q4 25 | $111.4M | $354.6M | ||
| Q3 25 | $-26.3M | $321.9M | ||
| Q2 25 | $-21.7M | $306.8M | ||
| Q1 25 | $-13.5M | $295.5M | ||
| Q4 24 | $-8.3M | $292.0M | ||
| Q3 24 | $-2.7M | $257.5M | ||
| Q2 24 | $45.8M | $243.0M | ||
| Q1 24 | $51.4M | $233.9M |
总资产SCORVCEL
| Q4 25 | $407.7M | $488.0M | ||
| Q3 25 | $406.9M | $453.3M | ||
| Q2 25 | $415.9M | $435.6M | ||
| Q1 25 | $421.5M | $424.6M | ||
| Q4 24 | $430.2M | $432.7M | ||
| Q3 24 | $412.5M | $390.4M | ||
| Q2 24 | $474.1M | $376.8M | ||
| Q1 24 | $477.7M | $356.7M |
负债/权益比SCORVCEL
| Q4 25 | 0.37× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $2.9M | $12.8M |
| 自由现金流率自由现金流/营收 | 3.1% | 13.8% |
| 资本支出强度资本支出/营收 | 0.3% | 2.4% |
| 现金转化率经营现金流/净利润 | 1.07× | 0.65× |
| 过去12个月自由现金流最近4个季度 | $21.8M | $24.7M |
8季度趋势，按日历期对齐
经营现金流SCORVCEL
| Q4 25 | $3.2M | $15.0M | ||
| Q3 25 | $9.5M | $22.1M | ||
| Q2 25 | $932.0K | $8.2M | ||
| Q1 25 | $9.1M | $6.6M | ||
| Q4 24 | $-10.0M | $22.2M | ||
| Q3 24 | $12.5M | $10.2M | ||
| Q2 24 | $8.7M | $18.5M | ||
| Q1 24 | $6.9M | $7.2M |
自由现金流SCORVCEL
| Q4 25 | $2.9M | $12.8M | ||
| Q3 25 | $9.4M | $19.5M | ||
| Q2 25 | $787.0K | $81.0K | ||
| Q1 25 | $8.7M | $-7.6M | ||
| Q4 24 | $-10.3M | $8.5M | ||
| Q3 24 | $12.4M | $-9.2M | ||
| Q2 24 | $8.5M | $1.8M | ||
| Q1 24 | $6.6M | $-6.8M |
自由现金流率SCORVCEL
| Q4 25 | 3.1% | 13.8% | ||
| Q3 25 | 10.5% | 28.8% | ||
| Q2 25 | 0.9% | 0.1% | ||
| Q1 25 | 10.1% | -14.5% | ||
| Q4 24 | -10.8% | 11.2% | ||
| Q3 24 | 14.0% | -15.9% | ||
| Q2 24 | 10.0% | 3.4% | ||
| Q1 24 | 7.6% | -13.3% |
资本支出强度SCORVCEL
| Q4 25 | 0.3% | 2.4% | ||
| Q3 25 | 0.1% | 3.9% | ||
| Q2 25 | 0.2% | 12.9% | ||
| Q1 25 | 0.4% | 27.0% | ||
| Q4 24 | 0.2% | 18.3% | ||
| Q3 24 | 0.1% | 33.5% | ||
| Q2 24 | 0.2% | 31.8% | ||
| Q1 24 | 0.3% | 27.3% |
现金转化率SCORVCEL
| Q4 25 | 1.07× | 0.65× | ||
| Q3 25 | 20.96× | 4.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -3.19× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
